Table 1.
Selected clinical trials that incorporate blinatumomab in experimental therapy of B-NHL.
| Drug Combination | Target Antigens | Mode of Action of the Combination Agent(s) Other Than Bispecific Antibody | Study Phase | Disease Status | Estimated Study Completion Date | ClinicalTrials.gov Identifier (Other Identifier) |
|---|---|---|---|---|---|---|
| blinatumomab | CD19/CD3 | 2 | R/R indolent B-NHL | December 2023 | NCT02811679 | |
| blinatumomab | CD19/CD3 | 1 | R/R indolent B-NHL | May 2022 | NCT02961881 | |
| blinatumomab | CD19/CD3 | 1 | DLBCL after ASCT | December 2023 | NCT03072771 | |
| blinatumomab + lenalidomide | CD19/CD3 | immunomodulatory agent lenalidomide | 1 | R/R B-NHL | December 2020 | NCT02568553 |
| blinatumomab + pembrolizumab | CD19/CD3 | immune check-point PD-1 inhibitor pembrolizumab | 1 | R/R DLBCL | January 2026 | NCT03340766 (KEYNOTE-348) |
Abbreviations: ASCT= autologous stem cell transplantation; DLBCL= diffuse large B-cell lymphoma; PD-1= programmed death 1; R/R= relapsed/refractory; B-NHL= B cell non-Hodgkin lymphomas.